ACC House Call: Current SGLT-2 Inhibitor Standing
A discussion with a Brigham and Women's Hospital cardiologist on the research of the add-on cardiometabolic drug class.
The SGLT-2 inhibitor drug class has progressed quickly in clinical cardiometabolic assessment and real-life use—from the management and reduction of type 2 diabetes (T2D) glucose levels, to the prevention of chronic kidney disease risk, and now to benefit for certain patients’ heart failure risks.
What will dictate their marketed labels and overall use among patients is the continuation of research beyond the current coronavirus (COVID-19) pandemic—and the dissemination of such research at future major meetings.
In a special edition House Call video interview with HCPLive®, Muthiah Vaduganathan, MD, MPH, a cardiologist at the Center for Advanced Heart Disease at Brigham and Women's Hospital, detailed what new trends and findings would have highlighted SGLT2 discussion at the American College of Cardiology (ACC) 2020 Scientific Sessions prior to its cancellation.
